86 related articles for article (PubMed ID: 17708065)
1. Effect of rifampicin pretreatment on the transport across rat intestine and oral pharmacokinetics of ornidazole in healthy human volunteers.
Kumar YS; Ramesh S; Rao YM; Paradkar AR
Drug Metabol Drug Interact; 2007; 22(2-3):151-63. PubMed ID: 17708065
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers.
Devandla A; Yamsani SK; Yamsani MR
Drug Metab Pers Ther; 2015 Dec; 30(4):257-61. PubMed ID: 26353177
[TBL] [Abstract][Full Text] [Related]
3. Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A.
Ramesh S; Kumar YS; Rao YM
Drug Metabol Drug Interact; 2006; 22(1):67-77. PubMed ID: 17152348
[TBL] [Abstract][Full Text] [Related]
4. Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers.
Jayasagar G; Krishna Kumar M; Chandrasekhar K; Madhusudan Rao Y
Drug Metabol Drug Interact; 2003; 19(4):287-95. PubMed ID: 14768975
[TBL] [Abstract][Full Text] [Related]
5. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein.
Machavaram KK; Gundu J; Yamsani MR
Drug Metabol Drug Interact; 2006; 22(1):47-65. PubMed ID: 17152347
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Br J Clin Pharmacol; 2013 Feb; 75(2):440-9. PubMed ID: 22642721
[TBL] [Abstract][Full Text] [Related]
7. Effects of sinapic acid on hepatic cytochrome P450 3A2, 2C11, and intestinal P-glycoprotein on the pharmacokinetics of oral carbamazepine in rats: Potential food/herb-drug interaction.
Raish M; Ahmad A; Ansari MA; Alkharfy KM; Ahad A; Al-Jenoobi FI; Al-Mohizea AM; Khan A; Ali N
Epilepsy Res; 2019 Jul; 153():14-18. PubMed ID: 30927680
[TBL] [Abstract][Full Text] [Related]
8. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Punyo J; Sunbhanich M
Clin Pharmacol Ther; 2002 Nov; 72(5):505-13. PubMed ID: 12426514
[TBL] [Abstract][Full Text] [Related]
9. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
Bidstrup TB; Stilling N; Damkier P; Scharling B; Thomsen MS; Brøsen K
Eur J Clin Pharmacol; 2004 Apr; 60(2):109-14. PubMed ID: 15034704
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
Zhang W; Deng S; Chen XP; Zhou G; Xie HT; He FY; Cao D; Li YJ; Zhou HH
Clin Ther; 2008 Jul; 30(7):1283-9. PubMed ID: 18691987
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
13. Investigation of chiral inversion and pharmacokinetics of laevo-ornidazole by high-performance liquid chromatography.
Mu LL; Cheng ZN; Guo X; Luo X; Yu P
J Clin Pharm Ther; 2013 Feb; 38(1):31-5. PubMed ID: 23167572
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of guar gum-based colon-targeted drug delivery systems of ornidazole in healthy human volunteers.
Krishnaiah YS; Indira Muzib Y; Bhaskar P
J Drug Target; 2003 Feb; 11(2):109-15. PubMed ID: 12881197
[TBL] [Abstract][Full Text] [Related]
16. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.
Mahatthanatrakul W; Nontaput T; Ridtitid W; Wongnawa M; Sunbhanich M
J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666
[TBL] [Abstract][Full Text] [Related]
17. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
19. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
20. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
Hamilton M; Wolf JL; Drolet DW; Fettner SH; Rakhit AK; Witt K; Lum BL
Cancer Chemother Pharmacol; 2014 Mar; 73(3):613-21. PubMed ID: 24474302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
